DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading ...

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump ...

Following similar deals in countries like the United States and the U.K., Canada is bolstering its stockpile of bird flu ...

Previous bird flu outbreaks and decades-old public health infrastructure have led industry to protect the hens used for ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

A meeting of the CDC's Advisory Committee on Immunization Practices (ACIP), which provides guidance on recommended vaccines and for which populations, scheduled for later this month has been postponed ...

Sanofi and Johnson & Johnson’s E. coli vaccine candidate failed to prevent invasive E. coli disease effectively.

The company announced its Q4 results after-market hours. Its shares ended 0.4% higher on Thursday at ₹4,759.35 on the BSE.

It’s a problem that’s been hovering since the 2017 Dengvaxia controversy led to the suspension of the Department of Health’s (DOH) vaccination campaign against this endemic scourge. On ...

Sanofi announces update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study: Paris Friday, February 14, 2025, 12:00 Hrs [IST] A scheduled review of the E.mbrace p ...